CATT Provides Reassuring Data On Anti-VEGF Use, But Some Questions Remain

Ocular Surgery News

One-year results of the CATT showed that there are alternatives to injecting ranibizumab every 4 weeks, but another year of investigation is needed to draw more definitive conclusions, according to Neil M. Bressler, MD, keynote lecturer at the Advanced Retinal Therapy meeting here.
  • <<
  • >>

Comments